Celularity Receives Orphan Drug Designation from U.S. FDA for Its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/Neu Positive Gastric and Gastroesophageal Junction Cancers

By
Justin.choi
-
0
10
Celularity Inc. announced the US FDA has granted Orphan Drug Designation for its investigational natural killer cell therapy, CYNK-101, for treatment of gastric/gastroesophageal junction cancer.
[Celularity Inc.]
Press Release